In recent years, deuterated pharmaceuticals (heavy drugs) have attracted significant attention as novel drug discovery modalities. While the stronger C–D bonds, as compared to C–H bonds, result in improved metabolic stability, the introduction of multiple deuterium atoms alters the physicochemical properties. Among the various methods developed for the synthesis of deuterated compounds, H/D exchange reactions are regarded as the most straightforward and useful. Herein, we developed a direct method for the multiple deuteration (H/D exchange reactions) of sodium cycloalkanecarboxylates bearing cyclopentane and cyclobutane rings using deuterium oxide, the most inexpensive deuterium source, in the presence of a Pt/C catalyst. Furthermore, deuterated cycrimine was synthesized from the deuterated sodium cyclopentanecarboxylate, and the effect of deuteration on lipophilicity was evaluated by a parallel artificial membrane permeability assay. Although no significant difference in lipophilicity was observed between the deuterated and hydrogenated forms, this study provides a useful method for the synthesis of deuterated compounds and a new synthetic approach to deuterated pharmaceuticals.
This study presents an efficient
and practical approach to the synthesis of deuterated pharmaceuticals through
platinum on carbon-catalyzed multiple deuteration of sodium cycloalkanecarboxylates
using deuterium oxide (D₂O) as an inexpensive deuterium source. This method
enables the direct introduction of multiple deuterium atoms into cyclopentane
and cyclobutane rings with excellent yields and high deuterium contents.
Furthermore, the authors established a new synthetic route to deuterated
cycrimine, demonstrating the applicability of this strategy to pharmaceutical
synthesis. This work provides a valuable synthetic platform for deuterium drug
discovery and offers new opportunities for exploring the effects of deuterium
incorporation on pharmaceutical properties.
Camptothecin (CPT) is a monoterpenoid indole alkaloid produced in several plants and is a clinically important natural resource that serves as the precursor for the semi-synthetic anticancer drugs such as topotecan and irinotecan. CPT possesses a characteristic quinoline-containing scaffold; however, the molecular mechanisms underlying the downstream steps of its biosynthetic pathway remain unclear. In this study, we identified 17-O-acetylcamptothecinic acid (1) in hairy roots of Ophiorrhiza pumila. The abundance of compound 1 was markedly reduced following methyl jasmonate treatment, concomitant with increased accumulation of CPT. Metabolite profiling of CPT-producing plants revealed that compound 1 predominantly accumulates in the roots of O. pumila, O. kuroiwai, and Nothapodytes nimmoniana, but was not detected in Camptotheca acuminata. Clear conversion of compound 1 into CPT was observed upon incubation with cell lysates prepared from O. pumila hairy roots as well as under chemical deacetylation conditions. These findings suggest that 17-O-acetylcamptothecinic acid is a plausible final biosynthetic intermediate of CPT in O. pumila and that a protection–deprotection strategy may operate in CPT biosynthesis, similar to those reported for other alkaloid pathways. Furthermore, the absence of this acetylated intermediate in C. acuminata suggests possible convergent evolution of CPT biosynthetic mechanisms among distinct plant lineages.
[Highlighted Paper selected by Editor-in-Chief]
Camptothecin (CPT) is a plant alkaloid and
an important natural resource for the anticancer drugs irinotecan and
topotecan. Despite its pharmaceutical importance, the final steps of CPT
biosynthesis remain unclear. In this study, the authors isolated 17-O-acetylcamptothecinic
acid from Ophiorrhiza pumila hairy roots and identified it as a
plausible late-stage precursor of CPT. This proposal was supported by its
efficient conversion into CPT by a soluble protein extract from the hairy roots
and by chemical deacetylation. These findings suggest that a protection-deprotection
strategy may operate during the final maturation of CPT in O. pumila.
Most radiopharmaceuticals are administered as injectable preparations and are therefore subject to sterility testing. Sterility testing usually requires a 14-d incubation period, which poses a significant challenge for short-lived radiopharmaceuticals because testing must be performed retrospectively. Advances in science and technology have led to the development of various rapid microbial detection methods, one of which is the nucleic acid amplification technique employing PCR. However, PCR is known to be inhibited by a variety of metal ions, and radiopharmaceuticals frequently contain metal ions as radionuclides or as additives, raising concerns regarding false-negative results. In the present study, PCR was performed in the presence of metal radionuclides and additives (ZnCl2, InCl3, LuCl3, YCl3, SnCl2, GaCl3, CuCl2, TlCl, and ZrOCl2) used in radiopharmaceuticals. Lutetium (Lu) and yttrium (Y) exhibited particularly strong PCR inhibitory ability across all enzyme systems tested, while zirconium (Zr) exhibited strong but markedly system-dependent inhibition, showing negligible inhibition with one of the enzyme systems tested. Addition of the chelating agent 2,2′,2″,2‴-(1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetic acid to Lu-containing samples restored amplification activity, suggesting that radiopharmaceuticals in their chelated form are unlikely to inhibit PCR. Furthermore, when we conducted an analysis using a mock sample that closely resembled the actual radiopharmaceutical, we observed PCR inhibition that appeared to be caused by excipients at concentrations higher than those of the radionuclide, suggesting that pretreatment may be necessary depending on the formulation.
Sterility testing of
radiopharmaceuticals requires a 14-day incubation, far longer than most
radionuclide half-lives, making PCR-based rapid detection an attractive option.
However, radiopharmaceuticals often contain metal ions that may inhibit PCR and
cause false-negative results. The authors tested nine metal species contained
in these products and showed that lutetium, yttrium and zirconium strongly
inhibited amplification, whereas the effects of other metals varied with the
PCR reagent. Chelation with DOTA restored amplification, and tests with mock
formulations suggested that excipients, rather than trace radionuclides, may be
the main cause of inhibition. Pretreatment may therefore be required for some
formulations.
Gelation film-coating (GFC) technology has attracted attention as a strategy to improve the swallowability and taste masking of oral solid dosage forms; however, its application to mini-tablets remains challenging because of their high specific surface area and manufacturing limitations. This study aimed to develop a simple and scalable GFC formulation for mini-tablets using standard film-coating equipment. A poly(vinyl alcohol)/polyethylene glycol graft copolymer (PVAPEG) was used as the base polymer, and various thickening agents were screened to optimize the gel formation, disintegration behavior, and surface adhesion. The formulations were evaluated in terms of maximum extrusion stress, disintegration time, dissolution performance, pharmacokinetics, sensory characteristics, and stability. Among the tested formulations, xanthan gum (XG) provided an optimal balance between reduced adhesion and controlled disintegration. GFC mini-tablets containing PVAPEG and XG significantly improved swallowability and bitterness masking compared to uncoated formulations, while maintaining rapid drug dissolution comparable to that of the reference product. Bioequivalence with the marketed product was confirmed, and accelerated stability studies demonstrated excellent stability of the formulation. These findings indicate that GFC mini-tablets based on PVAPEG and XG represent a robust and scalable formulation strategy that enhances patient acceptability without compromising the pharmaceutical performance.
Patient
adherence to solid oral dosage forms is often compromised by swallowing
difficulties and bitter taste. To address these challenges, Nakamichi et al.
developed an innovative gel-forming film coating for mini-tablets using
conventional pan-coating equipment. By combining a polyvinyl
alcohol–polyethylene glycol graft copolymer with xanthan gum, the coated
mini-tablets rapidly form a lubricating hydrogel layer upon contact with
saliva. This formulation significantly reduces surface friction and masks
bitterness while maintaining rapid drug dissolution and bioequivalence with
commercial products. These findings highlight a promising strategy for improving
medication acceptability, particularly among pediatric and geriatric patients.
Stick–slip (SS) behavior often disrupts the smooth flow of pharmaceutical powders during transfer and can impair product uniformity. In this study, binary powder systems consisting of ethenzamide and pharmaceutical excipients were investigated using a constant-volume shear cell method to clarify the factors governing SS behavior in mixed powder formulations. Eight pharmaceutical excipients with distinct particle properties were selected to analyze the effects on SS behavior as a function of the mixing ratio. X-ray computed tomography (XRCT) was used to characterize interparticle void structures in excipient powder beds. The SS amplitude and interval increased with increasing consolidation load. The addition of excipients progressively suppressed the SS behavior depending on their void characteristics. Although limited to discrete mixing ratios and static XRCT, excipients with a higher fraction of interparticle voids of moderate size (5.6–23 µm) tended to suppress SS behavior at lower mixing ratios. Correlation analyses revealed strong positive correlations between the SS amplitude and static resistance parameters, such as the angle of internal friction and cohesion, whereas correlations with steady-state flow parameters were weak when data across different consolidation loads were analyzed together. At a fixed consolidation load, SS amplitude showed a clearer correlation with the dynamic friction angle (φCSL), indicating that φCSL reflects a flow-related property of the powder bed at the critical state and shows relatively robust behavior against variations in consolidation conditions.
Poor powder flowability can disrupt
pharmaceutical manufacturing and compromise product quality. This study
investigated how pharmaceutical excipients influence stick-slip behavior in
ethenzamide-excipient binary powder mixtures using a constant-volume shear cell
method. X-ray computed tomography was employed to characterize interparticle
void-size distributions in excipient powders, providing insight into the role
of void structure in stick-slip suppression. Although stick-slip amplitude was
strongly affected by pre-shear load, the dynamic friction angle at the critical
state decreased consistently with increasing stick-slip suppression,
highlighting its potential as a reliable indicator of powder flowability.